258 related articles for article (PubMed ID: 22280478)
1. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
Miller JM; Beig A; Carr RA; Webster GK; Dahan A
Mol Pharm; 2012 Mar; 9(3):581-90. PubMed ID: 22280478
[TBL] [Abstract][Full Text] [Related]
2. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation.
Miller JM; Beig A; Krieg BJ; Carr RA; Borchardt TB; Amidon GE; Amidon GL; Dahan A
Mol Pharm; 2011 Oct; 8(5):1848-56. PubMed ID: 21800883
[TBL] [Abstract][Full Text] [Related]
3. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption.
Beig A; Miller JM; Dahan A
Eur J Pharm Biopharm; 2012 Jun; 81(2):386-91. PubMed ID: 22387337
[TBL] [Abstract][Full Text] [Related]
4. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone.
Dahan A; Miller JM; Hoffman A; Amidon GE; Amidon GL
J Pharm Sci; 2010 Jun; 99(6):2739-49. PubMed ID: 20039391
[TBL] [Abstract][Full Text] [Related]
5. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
Miller JM; Beig A; Carr RA; Spence JK; Dahan A
Mol Pharm; 2012 Jul; 9(7):2009-16. PubMed ID: 22632106
[TBL] [Abstract][Full Text] [Related]
6. Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation.
Miller JM; Dahan A
Int J Pharm; 2012 Jul; 430(1-2):388-91. PubMed ID: 22465550
[TBL] [Abstract][Full Text] [Related]
7. Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay.
Beig A; Miller JM; Lindley D; Carr RA; Zocharski P; Agbaria R; Dahan A
J Pharm Sci; 2015 Sep; 104(9):2941-7. PubMed ID: 25989509
[TBL] [Abstract][Full Text] [Related]
8. Striking the Optimal Solubility-Permeability Balance in Oral Formulation Development for Lipophilic Drugs: Maximizing Carbamazepine Blood Levels.
Beig A; Miller JM; Lindley D; Dahan A
Mol Pharm; 2017 Jan; 14(1):319-327. PubMed ID: 27981848
[TBL] [Abstract][Full Text] [Related]
9. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off.
Beig A; Miller JM; Dahan A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1293-9. PubMed ID: 23770429
[TBL] [Abstract][Full Text] [Related]
10. Methacrylate-Copolymer Eudragit EPO as a Solubility-Enabling Excipient for Anionic Drugs: Investigation of Drug Solubility, Intestinal Permeability, and Their Interplay.
Fine-Shamir N; Dahan A
Mol Pharm; 2019 Jul; 16(7):2884-2891. PubMed ID: 31120762
[TBL] [Abstract][Full Text] [Related]
11. Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect.
Sugano K
Int J Pharm; 2010 Mar; 387(1-2):103-9. PubMed ID: 20006692
[TBL] [Abstract][Full Text] [Related]
12. Toward Successful Cyclodextrin Based Solubility-Enabling Formulations for Oral Delivery of Lipophilic Drugs: Solubility-Permeability Trade-Off, Biorelevant Dissolution, and the Unstirred Water Layer.
Fine-Shamir N; Beig A; Zur M; Lindley D; Miller JM; Dahan A
Mol Pharm; 2017 Jun; 14(6):2138-2146. PubMed ID: 28505451
[TBL] [Abstract][Full Text] [Related]
13. Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.
Beig A; Agbaria R; Dahan A
PLoS One; 2013; 8(7):e68237. PubMed ID: 23874557
[TBL] [Abstract][Full Text] [Related]
14. Active intestinal drug absorption and the solubility-permeability interplay.
Porat D; Dahan A
Int J Pharm; 2018 Feb; 537(1-2):84-93. PubMed ID: 29102702
[TBL] [Abstract][Full Text] [Related]
15. Estimation of effective intestinal membrane permeability considering bile micelle solubilisation.
Sugano K
Int J Pharm; 2009 Feb; 368(1-2):116-22. PubMed ID: 18992315
[TBL] [Abstract][Full Text] [Related]
16. Theoretical investigation of passive intestinal membrane permeability using Monte Carlo method to generate drug-like molecule population.
Sugano K
Int J Pharm; 2009 May; 373(1-2):55-61. PubMed ID: 19429288
[TBL] [Abstract][Full Text] [Related]
17. The Solubility-Permeability Trade-Off of Progesterone With Cyclodextrins Under Physiological Conditions: Experimental Observations and Computer Simulations.
Sun L; Zhang B; Sun J
J Pharm Sci; 2018 Jan; 107(1):488-494. PubMed ID: 29031956
[TBL] [Abstract][Full Text] [Related]
18. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs.
Dahan A; Miller JM
AAPS J; 2012 Jun; 14(2):244-51. PubMed ID: 22391790
[TBL] [Abstract][Full Text] [Related]
19. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.
Cirri M; Mura P; Mora PC
Int J Pharm; 2007 Aug; 340(1-2):84-91. PubMed ID: 17531411
[TBL] [Abstract][Full Text] [Related]
20. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability.
Zakeri-Milani P; Barzegar-Jalali M; Azimi M; Valizadeh H
Eur J Pharm Biopharm; 2009 Sep; 73(1):102-6. PubMed ID: 19442726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]